Highlights BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Market Closed - Nasdaq Other stock markets 21:00:00 07/05/2024 BST			5-day change	1st Jan Change
27.79 ^USD	-1.07%		+8.47%	-31.16%

05-06	Certain Restricted Stock Unit Awards of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	CI
05-06	Certain Options of BridgeBio Pharma, Inc. are subject to a Lock-Up Agreement Ending on 6-MAY-2024.	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BridgeBio Pharma Shares Decline After Q1 Financial Results	05-02	MT
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q1 Revenue $211.1M	05-02	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-02	CI
BridgeBio Pharma, Inc. Presents Cardiac Magnetic Resonance Imaging Evidence Consistent with Clinical Improvement	04-07	CI
BridgeBio Pharma Sells License for Potential Heart Disease Treatment to Bayer in Deal Worth up to $310 Million	03-04	MT
BridgeBio Pharma, Bayer agree on licensing deal for heart disease drug in Europe	03-04	RE
Bridgebio Pharma and Bayer Announce European Licensing Agreement for Acoramidis in ATTR-CM	03-04	CI
BridgeBio Pharma Q4 Loss Widens as Revenue Declines	02-22	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Earnings Flash (BBIO) BRIDGEBIO PHARMA Posts Q4 Revenue $1.7M	02-22	MT
BridgeBio Pharma, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	02-22	CI
KKR to acquire a stake in health tech firm Cotiviti	02-14	RE
Bridgebio Pharma and Kyowa Kirin Announce Partnership with an Upfront Payment of $100 Million for an Exclusive License on Infigratinib in Skeletal Dysplasias in Japan	02-07	CI
BridgeBio Pharma Gets FDA Acceptance for NDA of Acoramidis	02-05	DJ
BridgeBio Pharma, Inc. Announces U.S. Food and Drug Administration Acceptance of New Drug Application for Acoramidis for the Treatment of Patients with Transthyretin Amyloid Cardiomyopathy	02-05	CI
BridgeBio Pharma, Inc. Shares Positive Results of Single-Arm Phase 3 Study of Acoramidis in Japanese Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) Including No Mortality Reported in the Trial at 30 Months	02-02	CI
AstraZeneca: positive trial in cardiac amyloidosis	02-02	CF
AstraZeneca celebrates latest successful trial of acoramidis in Japan	02-02	AN
Invitae Collaborates With BridgeBio Pharma for Rare Disease Therapeutics	01-30	MT
Invitae Partners with BridgeBio Pharma to Harness Genetic Insights for the Discovery of Rare Disease Therapeutics	01-30	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights BridgeBio Pharma, Inc.

Equities

BBIO

US10806X1028

Highlights

Filters